Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.
Dana Chase, MD
Advertisement
Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.
Articles by Dana Chase, MD
Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.
Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.
Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5